The Lever And Clinical Significance Of Lipoprotein-associated Phospholipase A2 In Patients With Coronary Artery Disease

Objective: To evaluate the serum lipoprotein-associated phospholipase A2(Lipoprtein-associated pholipase A2, Lp-PLA2) and high-sensitivity CRP levels in patients with coronary heart disease,and investigate them clinical significance.Methods: To select 107 patients of Ningxia Medical University Hospital cardiovascular disease form 2014 April to june,incluing 27 patients with stable angine pectoris,55 withnon ST segment elevation acute coronary Syndrome and 25 controls. all patients were took blood samples 5ml from elbow venous on the admission todetecting the serum level of Lp-PLA2 and high-sensitivity CRP.All the non ST segment elevation acute coronary Syndromepatients divided into three groups,Were given the 20 mg dose of atorvastatin, 40 mg dose of atorvastatin, and 10 mg dose of rosuvastatin therapy respectively, and non ST segment elevation acute coronary Syndrome patientswere took blood again after treatment five days. The level of serum Lp-PLA2 were detected by ELISA, The serum high-sensitivity CRP levels were detected by latex-enhanced turbidimetry.Results:(1) non ST segment elevation acute coronary Syndrome, stable angina pectoris in patients with Lp-PLA2 levels significantly higher than controls( 691.80±461.26;480.28±382.36 VS 245.68±362.32)(P<0.05).non ST segment elevation acute coronary Syndrome group Lp-PLA2 levels above stable angina group(691.80 ± 461.26 VS 480.28 ± 383.36)(P <0.05).non ST segment elevation acute coronary Syndrome, stable angina pectoris in patients with hs-CRP levels significantly higher than controls(5.77±2.35;4.64±2.13 VS 3.42±1.58)(P <0.05).non ST segment elevation acute coronary Syndrome group hs-CRP levels above stable angina group(5.77±2.35 VS 4.64±2.13)(P<0.05).(2)Non ST segment elevation acute coronary Syndrome Group serum Lp-PLA2 levels was significantly decreased after takeing 20 mg dose of atorvastatin, 40 mg dose of atorvastatin, and 10 mg dose of rosuvastatin treatment since five days(677.31 ± 457.45 VS 569.83±429.99; 668.07 ± 577.29 VS 327.75± 258.23;730.82 ± 344.32 VS 396.58 ± 264.85)(P<0.05).(3)In non ST segment elevation acute coronary Syndromepatients the levels of serum Lp-PLA2 taking 40 mg dose ofatorvastatin was decreased than taking 20 mg loading does of atorvastatin after fifth days’ s(340.33 ± 346.57 VS 107.49 ± 200.05)(P<0.05);takeing 10 mg dose of rosuvastatin was decreased than taking 20 mg dose of atorvastatin after treatment five days(334.24 ± 179.73 VS 107.49 ± 200.05)(P<0.05);takeing 10 mg dose of rosuvastatinwas no significant change in the degree of decline than taking 40 mg dose of atorvastatin after treatment five days(334.24 ± 179.73 VS 340.33 ± 346.57)(P> 0.05).Conclusions:1. The serum of Lp-PLA2, high-sensitivity CRP levels in patients with coronary heart disease was increased, and the serum Lp-PLA2, high-sensitivity CRP levels of stable angina, unstable angina, acute myocardial infarctionin turn increased.2.The statins can reduce the serum levels of Lp-PLA2.3. the10 mg dose of rosuvastatin compared with 20 mg dose of atorvastatin is obvious.in the patienttreatment,and compared with 40 mg dose of atorvastatin is nothing。...